| [1] |
Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors[J]. CA Cancer J Clin, 2018, 68(6):471-487.
|
| [2] |
Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States[J]. JAMA Oncol, 2017, 3(10):1335-1342.
|
| [3] |
Jensen RT, Bodei L, Capdevila J, et al. Unmet needs in functional and nonfunctional pancreatic neuroendocrine neoplasms[J]. Neuroendocrinology, 2019, 108(1):26-36.
|
| [4] |
Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system[J]. Histopathology, 2020, 76(2):182-188.
|
| [5] |
Shi M, Fan Z, Xu J, et al. Gastroenteropancreatic neuroendocrine neoplasms G3: novel insights and unmet needs[J]. Biochim Biophys Acta Rev Cancer, 2021, 1876(2):188637.
|
| [6] |
吴文铭, 陈洁, 白春梅, 等. 中国胰腺神经内分泌肿瘤诊疗指南(2020)[J]. 中国实用外科杂志, 2021, 41(6):601-617, 632.
|
| [7] |
王文权, 楼文晖, 刘亮. 胰腺神经内分泌肿瘤热点问题的思考[J]. 中华消化外科杂志, 2022, 21(8):1031-1037.
|
| [8] |
Ma ZY, Gong YF, Zhuang HK, et al. Pancreatic neuroendocrine tumors: a review of serum biomarkers, staging, and management[J]. World J Gastroenterol, 2020, 26(19):2305-2322.
|
| [9] |
Memeh KO, Vaghaiwalla T, Keutgen XM. Surgical treatment of non-functioning pancreatic neuroendocrine tumors: current controversies and challenges[J]. Journal of Pancreatology, 2020, 3(2):51-58.
|
| [10] |
Cloyd JM, Omichi K, Mizuno T, et al. Preoperative fluorouracil, doxorubicin, and streptozocin for the treatment of pancreatic neuroendocrine liver metastases[J]. Ann Surg Oncol, 2018, 25(6):1709-1715.
|
| [11] |
Garcia-Carbonero R, Sorbye H, Baudin E, et al. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas[J]. Neuroendocrinology, 2016, 103(2):186-194.
|
| [12] |
Li Y, Fan Z, Zhang F, et al. Neoadjuvant therapy in pancreatic neuroendocrine neoplasms: a systematic review and meta-analysis[J]. Front Oncol, 2022, 12: 981575.
|
| [13] |
Palmieri LJ, Dermine S, Barré A, et al. Medical treatment of advanced pancreatic neuroendocrine neoplasms[J]. J Clin Med, 2020, 9(6):1860.
|
| [14] |
Cives M, Strosberg J. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors[J]. Drugs, 2015, 75(8):847-858.
|
| [15] |
Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors[J]. N Engl J Med, 2014, 371(3):224-233.
|
| [16] |
Raymond E, Hammel P, Dreyer C, et al. Sunitinib in pancreatic neuroendocrine tumors[J]. Target Oncol, 2012, 7(2):117-125.
|
| [17] |
Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors[J]. N Engl J Med, 2011, 364(6):501-513.
|
| [18] |
Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors[J]. N Engl J Med, 2011, 364(6):514-523.
|
| [19] |
Mpilla GB, Uddin MH, Al-Hallak MN, et al. PAK4-NAMPT dual inhibition sensitizes pancreatic neuroendocrine tumors to everolimus[J]. Mol Cancer Ther, 2021, 20(10):1836-1845.
|
| [20] |
Vitali E, Boemi I, Tarantola G, et al. Metformin and everolimus: a promising combination for neuroendocrine tumors treatment[J]. Cancers, 2020, 12(8):2143.
|
| [21] |
Kurita Y, Kobayashi N, Hara K, et al. Effectiveness and prognostic factors of everolimus in patients with pancreatic neuroendocrine neoplasms[J]. Intern Med, 2023, 62(2):159-167.
|
| [22] |
Daskalakis K, Tsoli M, Angelousi A, et al. Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms[J]. Endocr Connect, 2019, 8(6):641-653.
|
| [23] |
Walter MA, Nesti C, Spanjol M, et al. Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis[J]. Cochrane Database Syst Rev, 2021, 11(11):CD013700.
|
| [24] |
Murase Y, Kudo A, Akahoshi K, et al. Surgery after sunitinib administration to improve survival of patients with advanced pancreatic neuroendocrine neoplasms[J]. Ann Gastroenterol Surg, 2021, 5(5):692-700.
|
| [25] |
Das S, Al-Toubah T, Strosberg J. Chemotherapy in neuroendocrine tumors[J]. Cancers, 2021, 13(19):4872.
|
| [26] |
Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2020, 31(7):844-860.
|
| [27] |
Morizane C, Machida N, Honma Y, et al. Effectiveness of etoposide and cisplatin vs irinotecan and cisplatin therapy for patients with advanced neuroendocrine carcinoma of the digestive system: the TOPIC-NEC phase 3 randomized clinical trial[J]. JAMA Oncol, 2022, 8(10):1447-1455.
|
| [28] |
Li K, Yuan J, Li Y, et al. Successful neoadjuvant chemotherapy for small-cell neuroendocrine carcinoma of the pancreas: a case report[J]. Front Oncol, 2021, 11:719422.
|
| [29] |
Spada F, Antonuzzo L, Marconcini R, et al. Oxaliplatin-based chemotherapy in advanced neuroendocrine tumors: clinical outcomes and preliminary correlation with biological factors[J]. Neuroendocrinology, 2016, 103(6):806-814.
|
| [30] |
Rogers JE, Lam M, Halperin DM, et al. Fluorouracil, doxorubicin with streptozocin and subsequent therapies in pancreatic neuroendocrine tumors[J]. Neuroendocrinology, 2022, 112(1):34-42.
|
| [31] |
Prakash L, Bhosale P, Cloyd J, et al. Role of fluorouracil, doxorubicin, and streptozocin therapy in the preoperative treatment of localized pancreatic neuroendocrine tumors[J]. J Gastrointest Surg, 2017, 21(1):155-163.
|
| [32] |
Chua J, Nafziger E, Leung D. Evidence-based practice: temozolomide beyond glioblastoma[J]. Curr Oncol Rep, 2019, 21(4):30.
|
| [33] |
Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors[J]. Clin Cancer Res, 2007, 13(10):2986-2991.
|
| [34] |
Squires MH, Worth PJ, Konda B, et al. Neoadjuvant capecitabine/temozolomide for locally advanced or metastatic pancreatic neuroendocrine tumors[J]. Pancreas, 2020, 49(3):355-360.
|
| [35] |
Kunz PL, Graham NT, Catalano PJ, et al. Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211)[J]. J Clin Oncol, 2023, 41(7):1359-1369.
|
| [36] |
Camus B, Cottereau AS, Palmieri LJ, et al. Indications of peptide receptor radionuclide therapy (PRRT) in gastroenteropancreatic and pulmonary neuroendocrine tumors: an updated review[J]. J Clin Med, 2021, 10(6):1267.
|
| [37] |
Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors[J]. N Engl J Med, 2017, 376(2):125-135.
|
| [38] |
Schiavo Lena M, Partelli S, Castelli P, et al. Histopathological and immunophenotypic changes of pancreatic neuroendocrine tumors after neoadjuvant peptide receptor radionuclide therapy (PRRT)[J]. Endocr Pathol, 2020, 31(2):119-131.
|
| [39] |
高瑞泽, 孙文兵, 周意明, 等. 介入治疗神经内分泌肿瘤肝转移的进展[J]. 中华普通外科杂志, 2023, 38(3):234-237.
|